摘要
JAK家族是JAK-STAT信号传导通路中的非受体型酪氨酸蛋白激酶,JAK2-STAT3作为JAK-STAT通路中的一个重要信号轴,它在肿瘤中的持续性激活可以通过影响细胞的生长、凋亡、周期等起到促进肿瘤发生发展的作用。JAK2突变,尤其是JAK2V617F突变的发现引发了JAK2抑制剂的研究热潮,为肿瘤的治疗提供了新的方向。JAK2抑制剂能削弱肿瘤细胞的恶性生物学行为,在有JAK2V617F突变的血液系统肿瘤以及JAK2-STAT3信号异常的实体肿瘤中都具有一定的治疗价值。
The Janus kinase（JAK）proteins are a family of intracellular nonreceptor tyrosine kinases involved in the JAK- STAT signaling pathway ,in which the JAK2 -STAT3 is the most important pathway. Aberrant activated JAK2- STAT3 signaling is involved in carcinogenesis by regulating cancer cell growth, apoptosis or cell cycle. Since mutations in JAK2, and in particular JAK2V617F, are discovered ,JAK2 inhibitors have been rapidly developed as targeted therapies for cancers. JAK2 inhibitor has the potential to be a successful treatment option in hematolog- ic malignancies with JAN2V617F mutation and in other solid cancers with aberrant JAK2 - STAT3 signaling.
出处
《现代肿瘤医学》
CAS
2013年第10期2389-2392,共4页
Journal of Modern Oncology
